e-602,cemiplimab
palleon pharma,regeneron,sanofi
['e-602', 'glimmer-01', 'erda']
yesterday we presented initial results from the phase 1 glimmer-01 trial of our lead oncology program, e-602, at #aacr23. the data validated proof of mechanism for our glyco-immunology approach. our team is leading advances in glyco-immunology drug development, a field based on 
Clinical-stage biotechnology company developing drugs that harness glyco-immunology to treat cancer and inflammatory diseases